Whilst preserving the chance at such a HBV Chinese
tender benitec would still do well to look at getting much more leverage out of its tt-033 HCV stake than it's present ~ 5%. Chinese gov getting hold of Asian rights to tt-033 would be enough of a catalyst to fire other shRNA proof of concepts into life.
Add to My Watchlist
What is My Watchlist?